Approval of cancer drugs is a multi-step process. After successful completion of clinical trials, companies submit a New Drug Application (NDA) or Biologics License Application (BLA) to regulatory bodies like the FDA or EMA. These submissions include comprehensive data on clinical trial results, manufacturing processes, and labeling. The regulatory bodies then review the data, conduct inspections, and may consult advisory committees before granting approval.
